A deep-dive series built on the 2026 Q3 earnings season, threading from the earnings panorama to the next-modality gold rush.
A cross-company read of the four domestic CXDMO players (WuXi AppTec, Asymchem, Pharmaron, Porton) and two global leaders (Samsung Biologics, Lonza) across 2026 Q3/9M - growth is back, but profit quality and order books separate the field.
Key takeawayGrowth and recovery coexist: WuXi mends, Asymchem's emerging business surges, some upstream still lags.
While China's CXDMOs win downstream orders, who makes the tools? A Q3/H1 read on seven upstream names - equipment duopoly (Tofflon, Truking), EPC (Morimatsu), resins & media (Nanomicro, OPM Biosolutions), reagents (ACROBiosystems, Sino Biological) - three tiers of localization, at different speeds.
Key takeawayPick-and-shovel layer: equipment catching up, consumables breaking through, reagents steady high-margin.
Peptides, ADCs and CGT have been pitched as the 'second growth curve' of CDMO for three years. The 2026 Q3 reports hand the microphone back to the financials: WuXi's TIDES booked RMB 11.52bn in 9M, WuXi XDC posted RMB 3.70bn in H1 with orders +50-62%, while Hoyuan and Porton's CGT revenues together are under RMB 0.3bn and still loss-making. Who is booking real revenue, and who is still drawing on the whiteboard?
Key takeawayRealization differs by an order of magnitude: TIDES strongest, ADC fastest, CGT still premature.
With the Q3 earnings season closed, the two pure-play global benchmarks - Samsung Biologics and Lonza - sit alongside China's four (WuXi AppTec, WuXi Biologics, Pharmaron, Asymchem). Three rulers - growth gap, real order flow, and the 232 tariff - show China's supply chain was not dismantled by the tariff.
Key takeawayChina's core base sits squarely in the Section 232 exemption zone — order shift favors China.
Hidden in the Q3 reports is a harder signal than revenue - capital expenditure. Six CDMOs' 2026 capex totals over RMB 20 bn and is still climbing into 2027. This piece decodes what they are building, where the inflection lies, and the risks.
Key takeawayThis round of expansion is order-backed capex; the inflection leans positive, not excess.
With Q3 earnings behind us, we shift the lens from 'who is making money' to 'which modalities are incubating the next wave of CDMO orders.' This piece takes stock—across peptides, gene editing, nucleic acids and bispecific/multispecific antibodies—of the dig-able trends, capacity levels and the hard data points we consider most important, with a CDMO-oriented cross-modality conclusion.
Key takeawayNext orders lie in complex-molecule platforms: peptides / nucleic acids / bispecifics / gene editing.